Determining factors of renal dysfunction during cisplatin chemotherapy

Săftescu,Sorin; Popovici,Dorel; Oprean,Cristina; Negru,Alina; Haiduc,Anita; Stanca,Simona; Malița,Daniel-Claudiu; Volovăț,Simona; Negru,Șerban

doi:10.3892/etm.2020.9516

January-2021 Volume 21 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2021 Volume 21 Issue 1

Full Size Image

Article Open Access

Determining factors of renal dysfunction during cisplatin chemotherapy

Authors:
- Sorin Săftescu
- Dorel Popovici
- Cristina Oprean
- Alina Negru
- Anita Haiduc
- Simona Stanca
- Daniel-Claudiu Malița
- Simona Volovăț
- Șerban Negru
View Affiliations / Copyright

Affiliations: Department of Oncology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, PhD Program, Department of Pathology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Cardiology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, PhD Program, Department of Ophthalmology, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Pediatrics, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Radiology and Medical Imaging, ‘Victor Babeș’ University of Medicine and Pharmacy, 300041 Timisoara, Romania, Department of Oncology, ‘Gr. T. Popa’ University of Medicine and Pharmacy, 700115 Iasi, Romania

Copyright: © Săftescu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 83
|
Published online on: November 26, 2020

https://doi.org/10.3892/etm.2020.9516
Expand metrics +

Abstract

Cisplatin remains one of the most active antineoplastic treatments used in oncology, being the most prestigious exponent of the golden age in chemotherapy at the end of the 20th century. This chemotherapeutic drug is used for curative or palliative treatments in testicular, ovarian, head and neck neoplasms, sarcomas and lymphomas. The limiting dose adverse effect of cisplatin is nephrotoxicity. The present study aimed to evaluate the magnitude of the damage to renal function and to identify the risk or protective factors in renal toxicity. The retrospective study was performed using 81 consecutive patients who underwent at least three cycles of cisplatin chemotherapy. The results indicate an average decline in glomerular filtration rate (GFR) of 9 ml/min. Women appear to be less by a decline in renal function (a relative decline of GFR of ‑5% for women compared to ‑9% for men). The decline in GFR was found to be proportional to age; overweight (not obese) individuals had the best renal function behavior under cisplatin treatment, while the association of anaemia appears to be a risk factor for renal toxicity. The use of cisplatin in oncology in the last years may have decreased, either by using combination chemotherapy instead of monotherapy, or by its displacement by newly discovered treatments (e.g., immunotherapy in lung cancer). Therefore, it is possible that the profile of patients who are exposed to this drug and the duration of exposure have been modified compared to previous studies. The objectives of the present study were to assess the magnitude of the renal function damage during cisplatin treatment and to identify the risk and the protective factors in term of renal toxicity.

View Figures

View References

1	Rosenberg B, Vancamp L and Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature. 205:698–699. 1965.PubMed/NCBI View Article : Google Scholar
2	Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol. 8:1777–1781. 1990.PubMed/NCBI View Article : Google Scholar
3	FDA Cisplatin label. urihttps://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdfsimplehttps://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s080lbl.pdf accessed Oct 10 2020.
4	Brown A, Kumar S and Tchounwou PB: Cisplatin-based chemotherapy of human cancers. J Cancer Sci Ther. 11(97)2019.Epub 2019 Apr 8. PMID: 32148661; PMCID: PMC7059781.PubMed/NCBI
5	Electronic medicines compendium (emc). urihttps://www.medicines.org.uk/emc/medicine/623#INDICATIONSsimplehttps://www.medicines.org.uk/emc/medicine/623#INDICATIONS accessed Oct 10 2020.
6	Milosavljevic N, Duranton C, Djerbi N, Puech PN, Gounon P, Lagadic Gossmann D, Dimanche Boitrel MT, Rauch C, Tauc M, Counillon L, et al: Nongenomic effects of cisplatin: Acute inhibition of mechanosensitive transporters and channels without actin remodelling. Cancer Res. 70(7514 7522)2010.PubMed/NCBI View Article : Google Scholar
7	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740(364 378)2014.PubMed/NCBI View Article : Google Scholar
8	Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD and Milowsky MI: A systematic review of strategies to prevent cisplatin induced nephrotoxicity. Oncologist. 22(609 619)2017.urihttps://doi.org/10.1634/theoncologist.2016-0319simplehttps://doi.org/10.1634/theoncologist.2016-0319. PubMed/NCBI View Article : Google Scholar
9	Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V and Arsenijevic N: Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 26(25)2019.PubMed/NCBI View Article : Google Scholar
10	Pabla N and Dong Z: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 73(994 1007)2008.PubMed/NCBI View Article : Google Scholar
11	Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S and Flombaum CD: Long term renal outcomes after cisplatin treat¬ment. Clin J Am Soc Nephrol. 11(1173 1179)2016.PubMed/NCBI View Article : Google Scholar
12	Cockcroft DW and Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron. 16:31–41. 1976.PubMed/NCBI View Article : Google Scholar
13	Ryan JL: Treatment of chemotherapy induced nausea in cancer patients. Eur Oncol. 6(14 16)2010.urihttps://doi.org/10.17925/EOH.2010.06.02.14simplehttps://doi.org/10.17925/EOH.2010.06.02.14. PubMed/NCBI View Article : Google Scholar
14	Casas A, Torroba B, Tapia B and Garcia-Del-Barrio MA: 4CPS- 114 dosing of platinum and taxanes in obese patients: A systematic review. Eur J Hosp Pharm Sci Pract. 26(A121)2019.
15	Wood PA and Hrushesky WJ: Cisplatin-associated anemia: An erythropoietin deficiency syndrome. J Clin Invest. 95:1650–1659. 1995.PubMed/NCBI View Article : Google Scholar
16	Minami H, Ohe Y, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y, Nokihara H, Sekine I, et al: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients? J Clin Oncol. 22:2901–2908. 2004.PubMed/NCBI View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Determining factors of renal dysfunction during cisplatin chemotherapy

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles